Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Lo, MW' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 32 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Wells, T; Rippley, R; Hogg, R; Sakarcan, A; Blowey, D; Walson, P; Vogt, B; Delucchi, A; Lo, MW; Hand, E; Panebianco, D; Shaw, W; Shahinfar, S
      The pharmacokinetics of enalapril in children and infants with hypertension

      JOURNAL OF CLINICAL PHARMACOLOGY
    2. Song, HC; Gu, XM; Riffel, K; Yan, K; Lo, MW
      Determination of a novel thrombin inhibitor in human plasma and urine utilizing Liquid chromatography with tandem mass spectrometric and ultraviolet detection

      JOURNAL OF CHROMATOGRAPHY B
    3. Koon, WS; Lo, MW; Marsden, JE; Ross, SD
      Heteroclinic connections between periodic orbits and resonance transitionsin celestial mechanics

      CHAOS
    4. Lo, MW; McCrea, JB; Shadle, CR; Hesney, M; Chiou, R; Cylc, D; Yuan, AS; Goldberg, MR
      Enalapril in RAPIDISC (wafer formulation): pharmacokinetic evaluation of anovel, convenient formulation

      INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    5. Riffel, KA; Song, HC; Gu, XM; Yan, K; Lo, MW
      Simultaneous determination of a novel thrombin inhibitor and its two metabolites in human plasma by liquid chromatography/tandem mass spectrometry

      JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
    6. Rippley, RK; Connor, J; Boyle, J; Bradstreet, TE; Hand, E; Lo, MW; Murphy, MG
      Pharmacokinetic assessment of an oral enalapril suspension for use in children

      BIOPHARMACEUTICS & DRUG DISPOSITION
    7. Barrett, JS; Batra, V; Chow, A; Cook, J; Gould, AL; Heller, AH; Lo, MW; Patterson, SD; Smith, BP; Stritar, JA; Vega, JM; Zariffa, N
      PhRMA perspective on population and individual bioequivalence

      JOURNAL OF CLINICAL PHARMACOLOGY
    8. Barrett, JS; Batra, V; Chow, A; Cook, J; Gould, AL; Heller, AH; Lo, MW; Patterson, SD; Smith, BP; Stritar, JA; Vega, JM; Zariffa, N
      Update to the PhRMA Perspective on Population and Individual Bioequivalence

      JOURNAL OF CLINICAL PHARMACOLOGY
    9. Dryden, RM; Lo, MW
      Breast milk lidocaine levels in tumescent liposuction

      PLASTIC AND RECONSTRUCTIVE SURGERY
    10. Lo, MW
      You're off your orbit! Response

      COMPUTING IN SCIENCE & ENGINEERING
    11. Lo, MW
      Satellite-constellation design

      COMPUTING IN SCIENCE & ENGINEERING
    12. Cohen, M; Theroux, P; Weber, S; Laramee, P; Huynh, T; Borzak, S; Diodati, JG; Squire, IB; Deckelbaum, LI; Thornton, AR; Harris, KE; Sax, FL; Lo, MW; White, HD
      Combination therapy with tirofiban and enoxaparin in acute coronary syndromes

      INTERNATIONAL JOURNAL OF CARDIOLOGY
    13. Sandwall, P; Lo, MW; Jonzon, B; Dalen, P; Furtek, C; Ritter, M; Alvan, G; McCrea, J; Sjoqvist, F
      Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P4502C19)

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    14. McCrea, JB; Cribb, A; Rushmore, T; Osborne, B; Gillen, L; Lo, MW; Waldman, S; Bjornsson, T; Spielberg, S; Goldberg, MR
      Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    15. LO MW; TOH J; EMMERT SE; RITTER MA; FURTEK CI; LU H; COLUCCI WS; URETSKY BF; RUCINSKA E
      PHARMACOKINETICS OF INTRAVENOUS AND ORAL LOSARTAN IN PATIENTS WITH HEART-FAILURE

      Journal of clinical pharmacology
    16. ANDERSON RD; LO MW
      ENDOSCOPIC MALAR MIDFACE SUSPENSION PROCEDURE

      Plastic and reconstructive surgery
    17. DEPRE M; LO MW; VANHECKEN A; DELEPELEIRE I; HAND EL; LOWRY R; CONNOR JG; MURPHY MG; FEVERY J; DESCHEPPER PJ
      MILD-TO-MODERATE HEPATIC INSUFFICIENCY DOES NOT AFFECT PHARMACOKINETICS AND PHARMACODYNAMICS OF TIROFIBAN

      Naunyn-Schmiedeberg's archives of pharmacology
    18. RITTER MA; FURTEK CI; LO MW
      AN IMPROVED METHOD FOR THE SIMULTANEOUS DETERMINATION OF LOSARTAN ANDITS MAJOR METABOLITE, EXP3174, IN HUMAN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION

      Journal of pharmaceutical and biomedical analysis
    19. HOWELL KC; BARDEN BT; LO MW
      APPLICATION OF DYNAMICAL-SYSTEMS THEORY TO TRAJECTORY DESIGN FOR A LIBRATION POINT MISSION

      The Journal of the astronautical sciences
    20. GOLDBERG MR; LO MW; CHRIST DD; CHIOU R; FURTEK CI; AMIT O; CARIDES A; BIOLLAZ J; PIGUET V; NUSSBERGER J; BRUNNER HR
      DUP-532, AN ANGIOTENSIN-II RECEPTOR ANTAGONIST - FIRST ADMINISTRATIONAND COMPARISON WITH LOSARTAN

      Clinical pharmacology and therapeutics
    21. LO MW; CHALFIN S
      RETROBULBAR ANESTHESIA FOR REPAIR OF RUPTURED GLOBES

      American journal of ophthalmology
    22. LO MW; LAM KW; SPONSEL WE
      MITOMYCIN-C PENETRATION INTO HUMAN SCLERA

      Investigative ophthalmology & visual science
    23. GOLDBERG MR; LO MW; DEUTSCH PJ; WILSON SE; MCWILLIAMS EJ; MCCREA JB
      PHENOBARBITAL MINIMALLY ALTERS PLASMA-CONCENTRATIONS OF LOSARTAN AND ITS ACTIVE METABOLITE E-3174

      Clinical pharmacology and therapeutics
    24. SPIELBERG S; MCCREA J; CRIBB A; RUSHMORE T; WALDMAN S; BJORNSSON T; LO MW; GOLDBERG M
      A MUTATION IN CYP2C9 IS RESPONSIBLE FOR DECREASED METABOLISM OF LOSARTAN

      Clinical pharmacology and therapeutics
    25. MCCREA JB; LO MW; FURTEK CI; RITTER MA; CARIDES A; WALDMAN SA; BJORNSSON TD; GOLDBERG MR
      KETOCONAZOLE DOES NOT EFFECT THE SYSTEMIC CONVERSION OF LOSARTAN TO E-3174

      Clinical pharmacology and therapeutics
    26. SICA DA; LO MW; SHAW WC; KEANE WF; GEHR TWB; HALSTENSON CE; LIPSCHUTZ K; FURTEK CI; RITTER MA; SHAHINFAR S
      THE PHARMACOKINETICS OF LOSARTAN IN RENAL-INSUFFICIENCY

      Journal of hypertension
    27. GOLDBERG MR; BRADSTREET TE; MCWILLIAMS EJ; TANAKA WK; LIPERT S; BJORNSSON TD; WALDMAN SA; OSBORNE B; PIVADORI L; LEWIS G; BLUM R; HERMAN T; ABRAHAM PA; HALSTENSON CN; LO MW; LU H; SPECTOR R
      BIOCHEMICAL EFFECTS OF LOSARTAN, A NONPEPTIDE ANGIOTENSIN-II RECEPTORANTAGONIST, ON THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS

      Hypertension
    28. MCCREA JB; LO MW; TOMASKO L; LIN CC; HSIEH JYK; CAPRA NL; GOLDBERG MR
      ABSENCE OF A PHARMACOKINETIC INTERACTION BETWEEN LOSARTAN AND HYDROCHLOROTHIAZIDE

      Journal of clinical pharmacology
    29. GOLDBERG MR; LO MW; BRADSTREET TE; RITTER MA; HOGLUND P
      EFFECTS OF CIMETIDINE ON PHARMACOKINETICS AND PHARMACODYNAMICS OF IOSARTAN, AN AT(1)-SELECTIVE NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST

      European Journal of Clinical Pharmacology
    30. LO MW; GOLDBERG MR; MCCREA JB; LU H; FURTEK CI; BJORNSSON TD
      PHARMACOKINETICS OF LOSARTAN, AN ANGIOTENSIN-II RECEPTOR ANTAGONIST, AND ITS ACTIVE METABOLITE EXP3174 IN HUMANS

      Clinical pharmacology and therapeutics
    31. MCCREA J; LO MW; KONG T; CRIBB A; GOLDBERG M; BJORNSSON T
      RARE DEFICIENCY OF THE CONVERSION OF LOSARTAN TO ITS ACTIVE METABOLITE, E3174

      Clinical pharmacology and therapeutics
    32. GOLDBERG MR; TANAKA W; BARCHOWSKY A; BRADSTREET TE; MCCREA J; LO MW; MCWILLIAMS EJ; BJORNSSON TD
      EFFECTS OF LOSARTAN ON BLOOD-PRESSURE, PLASMA-RENIN ACTIVITY, AND ANGIOTENSIN-II IN VOLUNTEERS

      Hypertension


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/08/20 alle ore 17:06:17